Brain Storm. PLURISTEM | Giving patients a better chance. Human embryonic stem cell-based therapeutics | biopharmaceuticals | cancer | telomerase | human embryonic stem cell | vaccine | Geron. StemCells, Inc. : Groundbreaking Science. Breakthrough Medicine. Neuralstem Stem Cell Research and Biotherapeutics Company. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial. Public release date: 25-Aug-2010 [ Print | E-mail Share ] [ Close Window ] Contact: Deanne Eagledeanneeagle@gmail.com 917-837-5866Neuralstem, Inc. Neuralstem, Inc. (NYSE Amex:CUR) announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells.
This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury. ASIA A refers to a patient with no motor or sensory function in the relevant segments and is considered to be complete paralysis. "We are filing an application with the FDA to test our spinal cord stem cells in a second medical condition with substantial unmet needs," said Neuralstem CEO and President, Richard Garr. Potential Mechanism of Therapeutic Action. InVivo Therapeutics. TEDxBoston - Frank Reynolds - Changing the Face of Neuroscience. Developing spinal cord injury treatment, researching paralysis cure and other neurological therapies.